Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

313
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
313
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

410
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
410
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

From the arrhythmia to the substrate: the role of atrial cardiomyopathy in atrial fibrillation management.

Acta cardiologica·2026
Same author

Cardiovascular Involvement in Erdheim-Chester Disease Presenting as Pericardial Tamponade: A Case Report and Multimodality Imaging Review.

Journal of clinical medicine·2026
Same author

Acute and Chronic Myocarditis in Men and Women.

Current heart failure reports·2026
Same author

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

International journal of molecular sciences·2026
Same author

Conduction system pacing in heart failure: from guidelines to evidence and real-world practice.

Acta cardiologica·2026

相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

推进心力衰竭护理:突破和新兴策略

Andrea Tedeschi1, Federico Barocelli2, Luigi Gerra1

  • 1Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.

Journal of clinical medicine
|October 29, 2025
PubMed
概括

最近的心力衰竭治疗提供了新的希望,包括治疗糖尿病和肥胖的新药,以及治疗三腹的干预措施. 先进的治疗方法旨在克服器官短缺,将护理转向精准医学.

关键词:
作为GLP-1受体的激动剂.没有细胞的DNA DNA.在循环死亡后的捐赠.精细的renoneone是一个.心脏衰竭是因为心脏衰竭.在进步方面取得了进展.整体的人工心脏三管的反,三管的反.在GDMT的升级中,GDMT的升级.

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

相关实验视频

Last Updated: Jan 13, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

科学领域:

  • 心脏病学 心脏病学
  • 内部医学 内部医学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 心力衰竭 (HF) 是一种复杂的综合征,尽管有进展,但死亡率很高.
  • 治疗惯性和剂量不足限制了当前的高频管理.
  • 了解高频连续性对于有效治疗至关重要.

研究的目的:

  • 审查近期治疗心力衰竭的进展,跨越护理连续性.
  • 突出高频管理的既定和新兴策略.
  • 讨论解决先进高频器官缺陷的创新问题.

主要方法:

  • 关于心力衰竭治疗的最新进展的文献综述.
  • 专注于基于药物和设备的干预措施.
  • 对高频管理新兴策略的分析.

主要成果:

  • 早期启动基础HF疗法可以减少心血管事件,但面临实施挑战.
  • 新型药物如芬瑞在心脏和脏方面有好处;GLP-1激动剂在HFpEF/HFmrEF方面有前途.
  • 通过导管干预三管吐和器官捐献/人工心脏的创新解决了先进的HF.

结论:

  • 在HF护理方面的进步包括精确指导疗法和多学科方法.
  • 新的药理学药剂和干预措施正在扩大治疗选择.
  • 解决实施中的挑战和器官短缺是未来高频率管理的关键.